2018 Archived Content
Track 10: Pharmaceutical R&D Informatics

Data sets are only continuing to grow larger as pharmaceutical companies generate and collect data from a number of sources, including R&D, clinical, translational, genomic, and health records, and these companies must effectively manage, integrate, and analyze this data to enable more informed decision-making. Furthermore, ensuring this data is of a high quality, consistent, and correct is key to analyzing data and developing actionable insights. Track 10 explores the progress made in the integration and analysis of complex data sets, generated both internally and externally, and real-world data to transform R&D and drive precision medicine.

Tuesday, May 15

7:00 am Workshop Registration Open (Commonwealth Hall) and Morning Coffee (Foyer)


8:0011:30 Recommended Morning Pre-Conference Workshops*

W1. Data Management for Biologics: Registration and Beyond


12:304:00 pm Recommended Afternoon Pre-Conference Workshops*

W10. Digital Biomarkers in Pharma R&D: Technical Challenges and Strategies for Advancing Personalized Medicine


* Separate registration required.

2:006:30 Main Conference Registration Open (Commonwealth Hall)

4:00 PLENARY KEYNOTE SESSION (Amphitheater & Harborview 2)

5:007:00 Welcome Reception in the Exhibit Hall with Poster Viewing (Commonwealth Hall)

Wednesday, May 16

7:00 am Registration Open (Commonwealth Hall) and Morning Coffee (Foyer)

8:00 PLENARY KEYNOTE SESSION (Amphitheater & Harborview 2)

9:45 Coffee Break in the Exhibit Hall with Poster Viewing (Commonwealth Hall)

DATA INTEGRATION, ANALYTICS, AND COLLABORATION 
Harborview 2

10:50 Chairperson’s Remarks

Yuriy Gankin, Vice President, Chief Life Science Officer, Life Sciences, EPAM Systems

11:00 R&D Informatics: Real-Time Data to Decisions

Anastasia Christianson, Vice President, R&D Operations IT, Oncology IT, Janssen

Pharma R&D needs to “democratize” data to make the right data available to the right audience at the right time to enable informed decision making. This starts with data management, standardization, and integration for easy access, including easy import into advanced analytics tools and the output to decision support tools.

11:30 Cross-Departmental Collaboration: Driving Pharma R&D Informatics

Joseph Lehar, Executive Director, Computational Biology, Merck Research Labs

This talk discusses cross-team collaboration and an overview of themes in R&D informatics that are driving solutions, drug discovery, and translational research.

 

12:00 pm Making Heterogeneous Data Accessible and Actionable Using Natural Language Processing and Machine Learning

John Brimacombe, Executive Chairman, Linguamatics

AI in the form of NLP-based text mining has proved its value in life sciences. However, there is potential for much wider impact. In this talk we will show next generation approaches to put the power of NLP into the hands of a broad user base for scientific knowledge discovery.

 

12:15 Creating a Connected Ecosystem to Gain Insights Across R&D

Kenneth Walker, PhD, Director, Research, Therapeutic Discovery, Amgen

Streamlining laboratory data exchange from molecular biology to preclinical remains a challenge. If an underlying platform is established to connect instruments and workflows, then it becomes possible to create a connected ecosystem. A connected ecosystem allows for R&D organizations to share data, make informed decisions, and derive insights.

12:30 Session Break

 

12:40 Luncheon Presentation I: Unleashing Digital Innovation with a Graph-Based Semantic Layer

Jim LaPointe, Managing Director, Life Sciences & Healthcare, Sales, Cambridge Semantics Inc.

Insightful­ analyses of internal & external R&D data are helping transform innovative biopharmaceutical companies to maximize the benefit of their therapeutic products. Graph-based, semantics layer driven R&D data lakes, based on the award winning Anzo Smart Data Lake® platform, rapidly integrates and harmonizes R&D data for immediate exploratory analytics at ‘big data’ scale.

 

1:10 Luncheon Presentation II: Celgene’s Journey to Become Information-Driven with Cognitive Search

Shefali Pathak, Global Search Service Owner, Search and Business Insights, Celgene

One of the biggest challenges facing pharmaceutical knowledge-workers is the information sprawl and limited availability of tools they can depend on to do their jobs and unify the information landscape. Learn how Celgene tackled these challenges with Sinequa’s Cognitive Search & Analytics platform to generate new insights from vast scientific research & enterprise data and accelerate business and product innovation.

1:40 Session Break

NEXT GENERATION DATA SCIENCE IN R&D
Harborview 2

1:50 Chairperson’s Remarks

Farida Kopti, PhD, Director, Chemistry/Pharmacology/HTS Informatics IT, Merck Research Labs, Merck & Co.

1:55 Next Generation R&D Data Science: The Takeda Data Science Institute

Eric Perakslis, PhD, Senior Vice President and Head, Takeda Data Science Institute; Strategy and Professional Affairs, Takeda Pharmaceuticals

Takeda R&D has developed a fully integrated Data Science Institute comprised of more than 170 diverse data science professionals that manage all aspects of R&D data science and that also serves as a center of excellence for all of Takeda. Comprised of informaticians, biostatisticians, epidemiologists, medical outcomes experts, data architects and experts in molecular profiling and digital devices this team drives all aspects of modern biopharmaceutical data science for Takeda.

2:25 The Intersection of Data Sciences and Life Sciences in Rare Diseases

John Reynders, Vice President, Data Sciences, Genomics, and Bioinformatics, Alexion Pharmaceuticals, Inc.

Novel and non-obvious applications of data sciences in rare-disease research, strategy, and business development. Multiple case-studies and examples will be shared along with an overview of underlying capabilities and methods.

 

2:55 A Collaborative Ecosystem Can be the Answer

Misha Kapushesky, PhD, CEO, Genestack

With the cost of sequencing being driven down, the amount of omics data produced is increasing at an unfathomable rate. The challenges now faced by pharmaceutical organisations is not the need for more data, but better integration, management and visualisation of all their data. The solution? A best of breed omics data ecosystem with flexible and modular architecture.

tellic3:10 Co-Presentation: Breaking Down Data Silos and Leveraging External and Unstructured Data to Improve R&D Decisions

Richard Wendell, Founder & CEO, tellic

Ranjith Raghunath, Director, Head, Platform and Tools, Data Center of Excellence, GSK

Derek Marren, Director, Research IT, Biology Systems & Data Integration, Eli Lilly

Topics include: 1) How companies can harness the power of external and unstructured data 2) Engaging the C-suite to break down legacy data and organizational silo's and drive innovation 3) Best practices for how R&D IT can engage the business.

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing (Commonwealth Hall)

INTEGRATION AND IMPLEMENTATION OF NEW PLATFORMS AND ARCHITECTURE
Harborview 2

4:00 Virtual Product Home

Etzard Stolte, PhD, Global Head Knowledge Management PTD, Pharma Technical Development, F. Hoffmann La Roche

During the last 3 years Roche Pharma Technical Development, a global organization of several thousand researchers, has implemented a one-stop-shop for product data and information. On the one hand, the underlying big data platform leverages a state-of-the-art analytics to help in automated integration, searching, find an expert, and other functionality. On the other hand, a huge curatorial effort reviewed and migrated millions of documents to improve integration quality.

 4:30 Things I Didn’t Know I Needed to Know before Attempting to Implement a Cloud-Based Genomics Data Environment

Enoch S. Huang, PhD, Executive Director, Head of Computational Sciences, Pfizer Worldwide Research and Development

This talk will describe the factors behind a major pharma’s effort to move genomics data processing and analysis to a public cloud environment in collaboration with a leading academic institution. I will discuss unanticipated challenges associated with implementation, most of which were not technical or funding-related. Nevertheless, I am optimistic about the future of this platform, and will be sharing the reasons why I believe that this strategy will ultimately produce sustainable solutions for pharma R&D.

4:40 Enabling the Integrated R&D Landscape: The Bayer Pharma R&D Integration Architecture Strategy

Martin Sjöholm, Senior Enterprise Architect, Bayer

Data is one of the most valuable assets of any R&D organization. The desired future state is to achieve “Data as an Asset”, unlocking the full potential of translating data into insights. Organizational and technical barriers often impede access to data assets, and effective access to them. So how can an R&D organization bridge those challenges? Our claim is that a well-defined strategy accompanied with clear guiding principles are key success criteria. The Bayer Pharma R&D Integration Architecture Strategy has a clear objective: to significantly increase the ability to quickly adapt the business by integrating processes and improving the accessibility of data assets. In this presentation we will share our experience from setting the strategy, and give advice to organizations looking for guidance on how to gradually evolve their ability to integrate processes and data.

 

5:00 Project Haystack: Universal Access to Corporate Research History

Andras Volford, Product Owner, JChem Engines, ChemAxon LLC

We present the results of an ongoing experimental project helping chemists and biologists discover information they don’t know exists: finding relevant data during design of drug candidates from idea to synthesis, universal, domain agnostic, simple access to the complete research history, indexing arbitrary amount of data and running structure search in a distributed environment.

 

5:15 Leveraging Modern Software to Organize, Optimize, and Measure Biologics R&D

Sajith Wickramasekara, CEO & Co-Founder, Benchling

Scaling biologics infrastructure is an enormous challenge faced by R&D IT. Benchling is a biologics-native informatics platform used by over 100,000 scientists to configure biologics workflows and run day-to-day R&D. This presentation will highlight how Benchling has helped leading biopharma companies organize, optimize, and measure their biologics R&D.

5:30 Best of Show Awards Reception in the Exhibit Hall with Poster Viewing (Commonwealth Hall)

 

7:0010:00 Bio-IT World After Hours @Lawn on D
 **Conference Registration Required. Please bring your conference badge, wristband, and photo ID for entry.   




Thursday, May 17

7:30 am Registration Open (Commonwealth Hall) and Morning Coffee (Foyer)

8:00 PLENARY KEYNOTE SESSION & Awards program (Amphitheater & Harborview 2)

9:45 Coffee Break in the Exhibit Hall and Poster Competition Winners Announced (Commonwealth Hall)

ARTIFICIAL INTELLIGENCE IN PHARMA R&D 
Harborview 2

10:30 Chairperson’s Remarks

Alok Tayi, CEO, TetraScience

10:40 The Promise and the Myth of AI in Transforming Biopharma

John Veytsman, Sr. Business Analyst, R&D Information Technology, Biogen

AI adoption has been mixed across biopharma. AI stands to transform how we work, how we research and how we discover new medicines. However, there is abundant confusion around what is AI, how does it work and what are the best use cases. Biogen is seeking to implement AI in various forms at points of highest leverage to help improve how we collaborate and how our scientists conduct research. This talk will walk through some of the ways AI has been adopted at Biogen and hopefully dispel some of the myths of what AI can do for biopharma.

11:10 Discovering Unknown Insights: How We Should Be Recycling Data, Not Just Our Trash

Derek Marren, Director, Research IT, Biology Results, Data Foundations, Laboratory Instrumentation Support Service & Neuroscience, Eli Lilly

As more data is collected and to achieve its maximum potential, there is value in semantically linking and connecting data sources to bring together public and proprietary/private data sources. Experience how Lilly and Open PHACTS have collaboratively created an innovative solution to ingest data from disparate sources into an ecosystem using graph databases within an open source environment. Once integrated, viewing the behavior in the data will present unforeseen and tease out new scientifically interesting insights that we desire to develop better understanding and support AI methods... the end game of driving toward better medicine and reuse of data connected and integrated data, combined with data handling philosophy that all can ascribe to and benefit from academic and pharma scientist alike.

 

11:40 A Pre-Competitive Technology Platform for Pharma

Joseph Donahue, Managing Director, Accenture

12:10 pm Session Break

 

12:20 Luncheon Presentation I: Managing Biomedical Data and Metadata in Large Scale Collaborations

Georges Heiter, Founder, Databiology

Data Commons and new Population Scale Omics and Imaging Projects continue to multiply. We will discuss strategies and solutions to address collaboration and data integration in a world lacking universal standards and with a plethora of regulatory frameworks. Join us together with leaders in large-scale biomedical collaborations to share insights about at some real world use cases.

 

12:50 Luncheon Presentation II: Zen and the Art of Data Science Maintenance

Jabe Wilson, PhD, Consulting Director, Text and Data Analytics, Elsevier, Inc.

You want insights from your Data: Use historic data for predictive modeling; Power virtualized R&D for data sharing; and, Mine Real World data to understand patients and markets. Is this an Art or a Science? Come learn how you can use current technologies to integrate multiple data sources into a semantic infrastructure, enabling delivery of data for machine learning processes.

1:20 Dessert Refreshment Break in the Exhibit Hall with Poster Viewing (Commonwealth Hall)

DATA HUBS FOR ADVANCED ANALYTICS
Harborview 2

1:55 Chairperson’s Remarks

Michael H. Elliott, CEO, Atrium Research and Consulting

2:00 R&D Data Hub – Connecting Data from Multiple Silos to Enable Analytics

Bryan Takasaki, PhD, Director, R&D Information US Lead, AstraZeneca

This talk will discuss AstraZeneca’s R&D data hub and how it is connecting data from multiple siloes to drive and enable operational dashboards and advanced analytics. We will examine the data warehouse approach, how data was integrated, and what types of reports and analytics are available for R&D projects.

2:30 An Advanced Analytics Platform to Maximize the Value of Our Small Molecule Project Data Hub

Roman Affentranger, Head, Small Molecule Discovery Workflows, Roche

We present a strategic platform for advanced analytics to maximize the value of our recently updated drug discovery project data hub. We will discuss specialized analytics extensions for chemistry and PK/PD, intelligent small-molecule building block search and filtering, integrated property prediction services, and broad data access to internal and external sources.

 

3:00 CO-PRESENTATION: Leveraging a R&D Data Hub Platform for Next Generation of Clinical Data Review

Krista McKee, Director, Data Analytics, Takeda

Raveen Sharma, Specialist Leader, Deloitte Consulting LLP

*Contributed work: Ramin Daron, Senior Director, Data Architecture, Takeda and Sunny Shahdadpuri, Senior Consultant, Deloitte Consulting LLP

The Data and Analytics Hub platform was conceived, designed, and built to address issues of data transparency, trust, and accessibility. This will support the efficient generation of insights for functions across R&D. In this presentation, we will focus on a critical use case of the platform, clinical data review/medical monitoring that will ultimately allow for efficient cross-study and cross-compound analysis which will advance our ability to interact with the data.

4:00 Conference Adjourns

Platinum Sponsors:

accenture

Dell EMC

Elsevier small logo

IBM_Blue

IDBS

Lucidworks

Microsoft

netapp